Loading...
JCR Pharmaceuticals Co., Ltd.
4552.T•JPX
HealthcareDrug Manufacturers - General
¥570.00
¥-20.00(-3.39%)
JCR Pharmaceuticals Co., Ltd. (4552.T) Financial Performance & Statements
Review JCR Pharmaceuticals Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
24.83%
↑ 24.83%
Operating Income Growth
51.40%
↑ 51.40%
Net Income Growth
46.00%
↑ 46.00%
Operating Cash Flow Growth
269.31%
↑ 269.31%
Operating Margin
-20.90%
↓ 20.90%
Gross Margin
65.29%
↑ 65.29%
Net Profit Margin
-14.39%
↓ 14.39%
ROE
-8.99%
↓ 8.99%
ROIC
-11.36%
↓ 11.36%
JCR Pharmaceuticals Co., Ltd. (4552.T) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for JCR Pharmaceuticals Co., Ltd. stock.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $9.22B | $8.51B | $8.14B | $9.15B |
| Cost of Revenue | $2.68B | $2.26B | $2.29B | $3.20B |
| Gross Profit | $6.55B | $6.25B | $5.86B | $5.96B |
| Gross Profit Ratio | $0.71 | $0.73 | $0.72 | $0.65 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $2.88B |
| SG&A Expenses | $3.21B | $6.70B | $6.37B | $6.23B |
| Operating Expenses | $6.56B | $6.70B | $6.37B | $6.23B |
| Total Costs & Expenses | $9.24B | $8.96B | $8.65B | $9.43B |
| Interest Income | $0.00 | $41.00M | $27.00M | $45.00M |
| Interest Expense | $0.00 | $37.00M | $26.00M | $23.00M |
| Depreciation & Amortization | $799.25M | $841.00M | $826.00M | $926.00M |
| EBITDA | $739.25M | -$163.00M | $1.22B | $649.00M |
| EBITDA Ratio | $0.08 | -$0.02 | $0.15 | $0.07 |
| Operating Income | -$15.00M | -$443.00M | -$510.00M | -$277.00M |
| Operating Income Ratio | -$0.002 | -$0.05 | -$0.06 | -$0.03 |
| Other Income/Expenses (Net) | $253.00M | -$482.00M | $73.00M | $150.00M |
| Income Before Tax | $238.00M | -$925.00M | $369.00M | -$127.00M |
| Income Before Tax Ratio | $0.03 | -$0.11 | $0.05 | -$0.01 |
| Income Tax Expense | $36.00M | -$40.00M | $164.00M | -$492.00M |
| Net Income | $115.00M | -$891.00M | $201.00M | $347.00M |
| Net Income Ratio | $0.01 | -$0.10 | $0.02 | $0.04 |
| EPS | $0.93 | -$7.15 | $1.61 | $2.78 |
| Diluted EPS | $0.94 | -$7.15 | $1.61 | $2.76 |
| Weighted Avg Shares Outstanding | $123.25M | $124.83M | $124.81M | $125.74M |
| Weighted Avg Shares Outstanding (Diluted) | $121.82M | $124.83M | $124.84M | $125.38M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan